This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Good Tidings for Gilead

Friday was a good day for Gilead Sciences (GILD - Get Report). Not only did it win U.S. marketing approval late Friday for a new drug to treat a life-threatening lung disease, but the drug's FDA-approved label should also give the company an advantage over its competition.

The drug, ambrisentan, which will now go by the brand name Letairis, will be used to treat pulmonary arterial hypertension (PAH), a chronic disease caused by constriction of the blood vessels that bring blood from the heart to the lungs. The disease affects about 200,000 patients worldwide.

However, Friday was a bad day for Encysive Pharmaceuticals (ENCY), which failed yet again to convince the FDA to approve its PAH drug Thelin. U.S. drug regulators sent Encysive its third "approvable letter" on Thelin, this time telling the company that it lacked enough evidence of efficacy to justify approval.

Before the FDA announcements, Gilead and Encysive shares closed Friday at $80.83 and $4.10, respectively. In Monday's premarket, Gilead shares traded for about $82, while Encysive shares were at $2.10.

With Encysive out of the way, Gilead's competition for PAH patients will come mainly from Tracleer, an older drug sold by Actelion. And that's a very good thing for Gilead, because the FDA-approved label for Letairis includes efficacy and safety data that show the drug to be best in class, with significant advantages over Tracleer.

Last year, Actelion booked Tracleer sales totaling $722 million. This year, the company is on track to sell about $800 million of the drug.

But not everything went Gilead's way Friday. Letairis' label does include a so-called "black box" warning regarding potential serious liver damage in patients treated with the drug. As a result, patients will be required to undergo monthly liver safety monitoring.

In an interview last month, Gilead Chief Scientific Officer Norbert Bischofberger said Letairis patients might not require regular liver safety monitoring because the incidence of liver toxicity associated with the drug is so low.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GILD $108.00 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%
GOOG $750.26 0.00%
TSLA $231.61 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs